GlassScriptPhysician profile
Laura B Bracknell
NPI 1578192282
$1,725.23
in general payments reported to CMS, 2019-2025
19 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $182 · 2022: $698 · 2023: $656 · 2024: $86.97 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $845.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $263.57 | 2022 | |
| Amgen INC. | $208.06 | 2022-2023 | Repatha |
| Horizon Therapeutics Plc | $200.00 | 2022-2023 | Krystexxa |
| Novo Nordisk INC | $159.94 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $144.00 | 2022-2023 | Arexvy, Shingrix |
| Pfizer INC. | $95.54 | 2023-2024 | |
| Exact Sciences Corporation | $94.56 | 2023-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $87.18 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.14 | 2023-2024 | Xifaxan |
| Abbvie INC. | $45.32 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $37.63 | 2023-2024 | Gvoke Hypopen |
| Boston Scientific Corporation | $33.50 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $33.27 | 2023 | Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $21.36 | 2023 | |
| Lilly USA, LLC | $14.77 | 2023 | Mounjaro |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.76 | 2023 | Vaxneuvance, Gardasil 9 |
| Recordati_rare_diseases_inc. | $12.36 | 2022 | |
| Currax Pharmaceuticals LLC | $12.05 | 2022 | |
| Phathom Pharmaceuticals, INC. | $5.32 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Bracknell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.